FDA 483 - Francis P. Worden, M.D. - April 04, 2023

An FDA inspection of Francis P. Worden, M.D., a clinical investigator in Ann Arbor, MI, revealed a significant deviation from an investigational plan. The firm failed to ensure subjects met eligibility criteria prior to enrollment, randomization, and treatment with investigational product. This indicates a serious lapse in adherence to study protocols.